The disclosure comes as another of Arcus's TIGIT trials flops.
ApexOnco Front Page
Recent articles
Lilly makes its second in vivo Car-T acquisition, buying the privately held Kelonia for $3.25bn.
It’s back to school for biotech, with a packed conference schedule.
Other new first-in-human trials involve CD74, where Gilead and Sutro tried and failed, and the emerging target MAT2A.
Bicara and DualityBio will soon test market appetite for new oncology issues.
Second time lucky for Zynyz, Amgen’s PRMT5 comeback, and other possible surprises.
Belrestotug’s lung cancer trial features among the ESMO late-breakers, as do Immutep, Scorpion and others.
The leading proponents of selective SMARCA2 inhibition are taking their oral projects into clinical trials.